Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Jun. 2025, Cardiac Biotech Solutions has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Cardiac Biotech Solutions (OTCPK:CBSC) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2025, Cardiac Biotech Solutions has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Cardiac Biotech Solutions Sloan Ratio % Related Terms
Cardiac Biotech Solutions Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBSC vs LUCY, NXGL, MHUAF: Sloan Ratio % Comparison
For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiac Biotech Solutions Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cardiac Biotech Solutions's Sloan Ratio % falls into.
Cardiac Biotech Solutions Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cardiac Biotech Solutions's Sloan Ratio for the fiscal year that ended in Mar. 2025 is calculated as
Cardiac Biotech Solutions's Net Income for the trailing twelve months (TTM) ended in Jun. 2025 was -0.264 (Jun. 2024 ) + -0.342 (Sep. 2024 ) + 0 (Mar. 2025 ) + -0.191 (Jun. 2025 ) = $-0.80 Mil.
Cardiac Biotech Solutions's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was -0.161 (Jun. 2024 ) + -0.181 (Sep. 2024 ) + 0 (Mar. 2025 ) + -0.141 (Jun. 2025 ) = $-0.48 Mil.
Cardiac Biotech Solutions's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2025 was 0 (Jun. 2024 ) + 0 (Sep. 2024 ) + 0 (Mar. 2025 ) + 0 (Jun. 2025 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiac Biotech Solutions (CBSC) has a Sloan Ratio % of 0.00% as of Jun. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' Sloan Ratio % too high?
Cardiac Biotech Solutions' current Sloan Ratio % is 0.00%.
How does Cardiac Biotech Solutions' Sloan Ratio % compare to LUCY and NXGL?
Cardiac Biotech Solutions' Sloan Ratio % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Sloan Ratio % of 0.00%. The current Sloan Ratio % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Sloan Ratio % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBSC has been successfully added to your 
